Walleye Capital LLC Ngm Biopharmaceuticals Inc Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $80,153 - $175,001	-133,589 Reduced 91.52%	12,380 $10,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $106,043 - $340,349	-100,994 Reduced 40.89%	145,969 $156,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $127,460 - $236,638	-52,238 Reduced 17.46%	246,963 $639,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $278,568 - $404,373	74,884 Added 33.38%	299,201 $1.22 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $714,899 - $2.71 Million	209,648 Added 1429.19%	224,317 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $184,682 - $259,201	14,669 New	14,669 $192,000
Q4 2021 Mar 03, 2022	SELL	$17.26 - $22.02 $386,071 - $492,543	-22,368 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $450,715 - $585,817	22,368 New	22,368 $470,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.